Sugi Predict

Sugi Predict / Compounds / SCHEMBL1998749

SCHEMBL1998749

SCHEMBL1998749

O=C(O)c1cc(Cl)ncc1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAPRT Q6XQN6 1/20 0.42
▸ TSHR P16473 2/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ SORT1 Q99523 2/20 0.40
▸ LCK P06239 1/20 0.40
▸ FYN P06241 1/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA3 P07451 1/20 0.39
▸ CA4 P22748 1/20 0.39
▸ CA6 P23280 1/20 0.39
▸ CA5A P35218 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ CA13 Q8N1Q1 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ CA5B Q9Y2D0 1/20 0.39
▸ HCAR2 Q8TDS4 2/20 0.38
▸ POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31220104 1.00 NAPRT (0.42) NAPRTTSHRHSD17B10SORT1LCK
Nitrous Acid SCHEMBL28883219 0.93 NAPRT (0.38) NAPRTTSHRHSD17B10SORT1LCK
SCHEMBL15689055 0.84 NAPRT (0.42) NAPRTTSHRHSD17B10SORT1LCK
SCHEMBL10287903 0.82 SIRT6 (0.46) TSHRCA12CA1CA2CA3
SCHEMBL29773884 0.81 NAPRT (0.47) NAPRTTSHRHSD17B10SORT1CA1
SCHEMBL979398 0.81 NAPRT (0.47) NAPRTTSHRHSD17B10SORT1CA1
SCHEMBL1300053 0.79 ALDH1A1 (0.47) NAPRTTSHRCA12CA1CA2
SCHEMBL2249284 0.79 HSD17B10 (0.43) TSHRHSD17B10SORT1LCKFYN
SCHEMBL29411268 0.79 ALDH1A1 (0.47) NAPRTTSHRCA12CA1CA2
SCHEMBL22290027 0.78 KMT2A (0.39) SORT1SMN1; SMN2ALDH1A1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713096-A1 CDK INHIBITOR COMPOUNDS Aleksia Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 — — US disclosed
US-12534456-B2 Heterocyclyl pyridines as novel fungicides BAYER AKTIENGESELLSCHAFT (DE) 2026-01-27 — — US disclosed
EP-4306529-B1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2026-01-21 — — EP disclosed
US-12522605-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2026-01-13 — — US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 — — US disclosed
US-12503471-B2 Triazatricycle compounds for the treatment of autoimmune disease HOFFMANN-LA ROCHE INC. (US) 2025-12-23 — — US disclosed
US-20250289801-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-09-18 — — US disclosed
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 — — US disclosed
US-12384776-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-12 — — US disclosed
CN-102209721-A Spirotetracyclic compounds as beta-secretase modulators and methods of use thereof AMGEN INC 2011-10-05 — — CN disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 — — WO disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 — — WO disclosed
EP-2328903-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2011-06-08 — — EP disclosed
US-20100087429-A1 SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2010-04-08 — — US disclosed
US-20100087429-A1 SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2010-04-08 — — US disclosed
US-20100087429-A1 SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2010-04-08 — — US disclosed
WO-2010030954-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2010-03-18 — — WO disclosed
WO-2010030954-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2010-03-18 — — WO disclosed
US-4746655-A ANTIHISTAMINES A. H. ROBINS COMPANY, INCORPORATED (US) 1988-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049074-A1 THIADIAZOLYL DERIVATIVES POLH, POLM, POLD1 NAPRT 3872/4885TSHR 2409/4885HSD17B10 440/4885
US-12384776-B2 Compounds and uses thereof VHL, TFEB, BECN1 NAPRT 2154/4885TSHR 4793/4885HSD17B10 2945/4885
US-20250270220-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 NAPRT 2567/4885TSHR 3357/4885HSD17B10 3669/4885
US-12534456-B2 Heterocyclyl pyridines as novel fungicides CBR1, CBR3, NOX1 NAPRT 468/4885TSHR 2818/4885HSD17B10 541/4885
US-20250289801-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 NAPRT 3262/4885TSHR 1212/4885HSD17B10 3130/4885
US-12509454-B2 Thiadiazolyl derivatives POLD1, POLQ, DNA2 NAPRT 2873/4885TSHR 4211/4885HSD17B10 617/4885
US-20100087429-A1 SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP NAPRT 2373/4885TSHR 2944/4885HSD17B10 1135/4885
US-12503471-B2 Triazatricycle compounds for the treatment of autoimmune disease SSB, HLA-DRB1, PKD1 NAPRT 3464/4885TSHR 53/4885HSD17B10 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.